General Proximity has entered a multi-target partnership with Daiichi Sankyo to apply the OmniTAC discovery platform to oncology programmes.
Daiichi Sankyo entered the collaboration through its Research Institute, located in Boston in the US state of Massachusetts.
The partnership will focus on discovering and advancing induced proximity medicines for cancer treatment.
These medicines facilitate accurate and selective alteration of proteins responsible for disease, thereby opening up therapeutic possibilities for targets that have been challenging to tackle using traditional methods.
The approach employs small molecules for bringing two proteins into close proximity, subsequently inducing a specific therapeutic effect.
General Proximity’s OmniTAC platform enables unbiased screening of effector proteins that can modulate disease-relevant targets, offering a distinct pathway for drug discovery.
General Proximity founder and CEO Armand Cognetta stated: “Daiichi Sankyo is a leader in oncology research and development, and we are excited to work with such a strong collaborator.
“This agreement represents an important validation of our novel induced proximity approach and highlights the potential of our OmniTAC discovery platform to deliver innovative solutions for patients.”
General Proximity will utilise OmniTAC to identify and characterise new effector-target pairs that could lead to first-in-class therapeutic candidates.
The company will broaden the use of the platform by utilising accurate control of proximity to target previously undruggable molecules across disease sectors.
Beyond oncology, General Proximity is progressing programmes in longevity, cardiometabolic conditions and neurodegeneration.
It develops next-generation induced proximity therapies and is advancing several preclinical programmes that are generated by the OmniTAC platform.
In January 2025, Daiichi Sankyo finalised the acquisition of intellectual property rights for gatipotuzumab, an anti-tumour-associated mucin-1 antibody, from Glycotope for $132.5m.
